RANDY KAUK: Open Payments
NPI 1982131702 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,086 in 34 payments from 12 companies in 2025. Trend: 2023 $313 · 2024 $783 · 2025 $2,086
Food & beverage: $2,086
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 4 | $409 |
| Tris Pharma Inc | 9 | $289 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $269 |
| Alkermes, Inc. | 3 | $228 |
| ABBVIE INC. | 2 | $197 |
| MERZ NORTH AMERICA, INC. | 1 | $169 |
| Corium, LLC | 7 | $125 |
| E.R. Squibb & Sons, L.L.C. | 1 | $123 |
| Otsuka America Pharmaceutical, Inc. | 1 | $121 |
| Neurocrine BioSciences, Inc. | 1 | $118 |
Products named: FANAPT, Dyanavel XR, CAPLYTA, LYBALVI, VRAYLAR, REXULTI, Azstarys, COBENFY.
Industry payments across AZ — which companies pay providers there.
